Stem cells therapy, page-6

Thank you Moreforme: agreed. Must now clearly demonstrate efficacy. Completed CTs will sort products (& coys). Potential useful regen med IP acquisition opportunities from undercapped AUS goldfish w/o $ to fund CTs. Ocker style pollies magic $20 bil biomed research fund a turd w/ $ going to same old gov/res inst players who would not know commercialisation if it kicked them in the bum.
Skepticism about regen med claims w/ some coys justified. AUS SCT small cap biotechs in a rough spot-AUS cap mkt a skint joke & marginal claims to keep capitalised not unusual. & TGA just chained AUS SCT sector while US & Japan streamlining trials & approvals. w/ v/ high relative AUS op costs, goldfish-in-ocean capital (& potential sales) mkt & TGA dithering, overseas mkt & ops ultimately only way to go IMO. Advice for AUS SCT biotechs (& renewable energy tech) - get out of AUS mkt as fast as you can. If coys regen med ultimately successful they will end up there anyway.
msb US mkt jump wise short term pain for potential LT gain IMO.